Mark R. Kelley

Chief Scientific Officer at Apexian Pharmaceuticals

Mark is currently the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor, Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology, Indiana University School of Medicine. He is also the Associate Director, Herman B Wells Center for Pediatric Research and the Associate Director for Basic Science Research at the IU Simon Cancer Center.

Mark completed his postdoctoral Fellowship at The Rockefeller University, New York, NY after earning his M.S. and Ph.D. from Louisiana State University, Baton Rouge, LA in 1984.

Mark holds numerous patents related to the use of DNA repair targets for cancer and has published over 166 articles in peer reviewed journals as well as 28 reviews and book chapters in numerous national and international journals. He also serves on the consulting and scientific boards of several biotechnology companies and serves on various NIH/NCI study sections and Cancer Center review panels. He was chair of the Cancer Etiology Study Section at NIH. He has also reviewed for international agencies. He is a member of American Association for the Advancement of Science, American Association for Cancer Research, Society for Pediatric Research, and American Society of Clinical Oncology.

Timeline

  • Chief Scientific Officer

    Current role

View in org chart